Oxford Global Genome Editing and Transgenic 2017 Boston

  • Conference Call
  • Oxford Global Ltd. is invit­ing you to join the Genome Edit­ing and Trans­genic Con­gress USA 2017, held on May 1011, 2017 in Boston, Mass­a­chu­setts.

    Over 20 pre­sen­ta­tions ded­i­cated to genome edit­ing tech­nolo­gies and the appli­ca­tions of genome edit­ing in a range of ther­a­peu­tic areas, includ­ing mus­cu­lar dys­tro­phy, car­dio­vas­cu­lar dis­eases, genetic dis­or­ders and immunotherapies.

    Includ­ing inter­ac­tive ses­sions focus­ing on:

    • Genome Edit­ing Techniques
    • Ther­a­peu­tic Appli­ca­tions of Genome Editing
    • Drug Dis­cov­ery & Devel­op­ment Applications

    Con­firmed Speakers

    • Wojtek Auer­bach, Senior Direc­tor Embry­onic Stem Cell Tech­nolo­gies – Regeneron
    • James Carothers, Assis­tant Pro­fes­sor of Chem­i­cal Engi­neer­ing – Uni­ver­sity of Washington
    • Zheng-​Yi Chen, Asso­ciate Pro­fes­sor – Har­vard Med­ical School
    • André Choulika, Chief Exec­u­tive Offi­cer – Cellectis
    • George Church, Pro­fes­sor of Genet­ics & Health Sci­ences & Tech­nol­ogy – Har­vard Uni­ver­sity & Mass­a­chu­setts Insti­tute of Tech­nol­ogy (HST)
    • Guru­murthy Channabasava­iah, Direc­tor, Trans­genic Core Facil­ity – Uni­ver­sity of Nebraska Med­ical School
    • Jim Collins, Pro­fes­sor – Mass­a­chu­setts Insti­tute of Technology
    • Lev Fedorov, Direc­tor of OHSU Trans­genic Mouse mod­els Shared Resource – Knight Can­cer Insti­tute at Ore­gon Health & Sci­ence University
    • Nicholas Gale, Senior Direc­tor Ther­a­peu­tic Tar­get Dis­cov­ery – Regeneron
    • Nas­reen Haque, Asso­ciate Pro­fes­sor – New York Med­ical School
    • William Theodorus Hen­driks, Instruc­tor in Neu­rol­ogy Mass­a­chu­setts Gen­eral Hos­pi­tal – Har­vard Med­ical School
    • Rob Howes, Direc­tor, Reagents and Assay Devel­op­ment, Dis­cov­ery Sci­ences – AstraZeneca
    • Sang Yong Kim, Direc­tor of Rodent Genetic Engi­neer­ing Lab­o­ra­tory and Research Asso­ciate Pro­fes­sor – NYU School of Medicine
    • Melissa Lar­son, Tech­ni­cal Direc­tor – Uni­ver­sity of Kansas Med­ical Centre
    • Mar­cello Maresca, Asso­ciate Prin­ci­pal Sci­en­tist – AstraZeneca
    • Danilo Mad­dalo, Prin­ci­pal Sci­en­tist – Novartis
    • John McLaugh­lin, Direc­tor of the Trans­genic and Embry­onic Stem Cell Core Shared Resource and Asso­ciate Pro­fes­sor – Ohio State University
    • Thom Saun­ders, Direc­tor of the Trans­genic Ani­mal Model Core and Research Asso­ciate Pro­fes­sor – Uni­ver­sity of Michigan
    • Toru Takeo, Assis­tant Pro­fes­sor, Divi­sion of Repro­duc­tive Engi­neer­ing, Cen­ter for Ani­mal Resources and Devel­op­ment – Kumamoto University
    • William Velander, Pro­fes­sor – Uni­ver­sity of Nebraska
    • Hart­mut Weiler, Direc­tor Trans­genic Core and Asso­ciate Pro­fes­sor – Med­ical Col­lege of Wisconsin

    Genome Edit­ing: Top­ics and Agenda

    The genome edit­ing mar­ket rep­re­sents a sig­nif­i­cant area of research within the genomic field. Advances in util­is­ing the lat­est CRISPR/​Cas9 and TALEN tech­nolo­gies, novel dis­ease mod­el­ling tech­niques as well as recent key safety and reg­u­la­tory issues all under­pin the vast poten­tial of the market’s suc­cess. In addi­tion to this, experts have high­lighted that the global genome edit­ing mar­ket is expected to reach $5.54 bil­lion by 2021.

    In keep­ing with Oxford Global’s highly suc­cess­ful Genomics and Genet­ics Research series, an expert panel of over 25 speak­ers will present a full con­fer­ence pro­gramme cov­er­ing the top­ics out­lined below:

    Day 1

    Morn­ing Ses­sion – Genome Edit­ing Technologies

    • Comparing/​contrasting dif­fer­ent genome edit­ing tech­nolo­gies: CRISPRs, ZFNs, TAL­ENs, AAVs
    • Novel tech­niques in CRISPR technology
    • Gene acti­va­tion and inhi­bi­tion using dead Cas9
    • Gene deliv­ery sys­tems: viral and non-​viral, nucleic acid, protein

    Stream 1: Drug Dis­cov­ery & Devel­op­ment Applications

    • Achiev­ing edit­ing and con­trol at whole-​genome scale
    • Genome edit­ing approaches to accel­er­ate drug discovery:
      • Tar­get iden­ti­fi­ca­tion, val­i­da­tion and screening
      • Engi­neer­ing ani­mal mod­els for in vivo study
      • Stem cell engi­neer­ing for drug screen­ing and discovery
      • Dis­ease mod­el­ling techniques

    Stream 2: Ther­a­peu­tic Appli­ca­tions of Genome Editing

    Case stud­ies from the areas of:

    • Car­dio­vas­cu­lar diseases
    • Dia­betes
    • Genetic dis­or­ders
    • Cys­tic Fibrosis
    • Can­cer

    Day 2

    Stream 1: Drug Dis­cov­ery & Devel­op­ment Applications

    • Achiev­ing edit­ing and con­trol at whole-​genome scale
    • Genome edit­ing approaches to accel­er­ate drug discovery:
      • Tar­get iden­ti­fi­ca­tion, val­i­da­tion and screening
      • Engi­neer­ing ani­mal mod­els for in vivo study
      • Stem cell engi­neer­ing for drug screen­ing and discovery
      • Dis­ease mod­el­ling techniques

    Stream 2: Ther­a­peu­tic Appli­ca­tions of Genome Editing

    Case stud­ies from the areas of:

    • Car­dio­vas­cu­lar diseases
    • Dia­betes
    • Genetic dis­or­ders
    • Cys­tic Fibrosis
    • Can­cer

    After­noon Ses­sion: Genome Edit­ing Technologies

    • Advanc­ing CRISPR technology
    • Devel­op­ment of deliv­ery solu­tions for genome editing
    • Deliv­ery of dif­fer­ent mod­i­fi­ca­tions: knock­down, knock­out, knockin
    • Soft­ware and bioin­for­mat­ics aspects of genome editing
    • Reg­u­la­tory issues in US genome edit­ing; com­par­i­son to dif­fer­ence reg­u­la­tory guide­lines (US, EU mainly)

    Trans­genic Tech­nolo­gies: Top­ics and Agenda

    Trans­genic tech­nolo­gies for ani­mal mod­els is advanc­ing pro­gres­sively with pio­neer­ing research tak­ing place in the field. The emer­gence of CRISPR/​Cas9 in recent years has become more acces­si­ble to researchers for bet­ter effi­ciency and pre­ci­sion in genetic screen­ing and genome edit­ing of trans­genic models.

    Our inau­gural Trans­genic USA Con­gress will have over 250 del­e­gates rep­re­sent­ing the lead­ing research & aca­d­e­mic insti­tu­tions and clin­i­cal research insti­tu­tions in the USA, as well as lead­ing phar­ma­ceu­ti­cal and biotech com­pa­nies from around the globe.

    Key experts will cover the below topic areas:

    Day 1

    Stream 1: Tech­nol­ogy Workshop

    • Ther­a­peu­tic Appli­ca­tion of Trans­genic Genome Editing
    • Improve­ment of in vivo CRISPR-​Cas genome engineering
    • Novel mouse genome engi­neer­ing tools
    • Mouse trans­ge­n­e­sis: pro­gram­ma­ble nucleases
    • Geno­typ­ing strate­gies and tools

    Stream 2: Tech­nol­ogy Workshop

    • Advances in Ani­mal Biotech­nol­ogy: Dis­cov­ery & Development
    • In vivo CRISPR genetic screen­ing for pre­ci­sion med­i­cine and drug discovery
    • Design­ing the right genes
    • Case stud­ies:
      • Gene edit­ing in pigs
      • Rare genetic disorders

    After­noon Ses­sion: Gen­er­a­tion of Trans­genic Mod­els – Mod­els of Dis­ease and Applications

    • Gen­er­at­ing trans­genic mouse mod­els of neu­rode­gen­er­a­tive diseases
    • Trans­genic rodent and other ani­mal mod­els of diseases
    • Trans­genic mod­els of oncol­ogy, car­dio­vas­cu­lar dis­ease and meta­bolic disorders
    • Organ trans­plan­ta­tion from trans­genic ani­mals into human beings
      • Eth­i­cal considerations
      • Explor­ing reg­u­la­tory pathways

    Day 2

    Morn­ing Ses­sion: Genet­ics, Epi­ge­net­ics, Stem Cell Manipulation

    • Genome and epi­ge­netic edit­ing appli­ca­tions in stem cells
    • Gene reg­u­la­tion and RNA biology
    • Pluripo­tent stem cell-​based dis­ease models
    • Somatic cell nuclear trans­fer (SCNT)
    • Mam­malian syn­thetic biology
    • CRISPR-​Cas genome editing
      • How to reduce the chance of off-​target effects
      • How to reduce the chance of mosaicism

    Stream 1: Ther­a­peu­tic Appli­ca­tion of Trans­genic Genome Editing

    • Cry­op­reser­va­tion of mouse embryos
    • Embryo vit­ri­fi­ca­tion
    • Mouse 3D imag­ing strategies
    • High through­put adult phenotyping
    • Pre­cise tar­geted genome editing

    Stream 2: Novel Trans­genic Technologies

    • Implan­ta­tion and injec­tion systems
    • Repro­gram­ming and trans­d­if­fer­a­tion techniques
    • Recom­bi­na­tion vectors
    • Transposon-​delivered transgenes
    • Plasmid-​based techniques

    Sub­mit a Poster

    For atten­dees inter­ested in sub­mit­ting a poster, there are oppor­tu­ni­ties now avail­able. Your poster pre­sen­ta­tion will be located in the exhi­bi­tion room for two days along­side other posters from those work­ing at the fore­front of Genome Edit­ing research and the Trans­genic field.

    How to sub­mit your abstract

    We will require:

    • Poster title, Abstract (200 words or less)
    • Prin­ci­pal author, Organisation
    • Mail­ing address, Email, Tele­phone, Fax
    • Addi­tional authors

    In order to secure your board space a fee of £250 plus VAT will be required. The poster should be pre­sented as A0 (841mm x 1189mm) por­trait size. To take advan­tage of this oppor­tu­nity you need to be reg­is­tered as a paid del­e­gate over the 2 days. We have lim­ited spaces avail­able, so please reg­is­ter soon!

    starting: ending: 11.05.2017 Location: , Category:

    Timeline

    Conference START 11.05.2017 END

    All deadlines have expired!

    This conference has no more open deadlines. There may be successive conferences coming up you may by interested in.

    Please check our conference list and search...

    Conference Facts

    Location , Address Avenue Louis Pasteur 77 Category Organiser More Info Conference Website

    Further interesting Conferences

    discover MORE CONFERENCES